DM199 is a synthetic form of the human tissue kallikrein 1 protein (KLK1), which is produced mainly in the kidneys, pancreas and salivary glands. DM199 has the potential to treat several diseases where sufficient levels of KLK1 are necessary for healthy function.
ReMEDy2 is a Phase 2/3 study investigating a novel acute ischemic stroke (AIS) treatment intended to safely:
In a patient population with no treatment options.
VISIT ON CLINICALTRIALS.GOVAn open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
VISIT ON CLINICALTRIALS.GOVFor more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of this product have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
